secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-05-11T20:10:44+00:00
Accession:  0001193125-26-216777
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports Q1 2026 net loss of $26.2M; cash raised to $271M
--------------------------------------------------------------------------------

- Net loss $26.2M ($0.25/share) vs. $18.2M net loss in Q1 2025; R&D spend up 50% YoY to $21.4M.
- Cash, equivalents & short-term investments $271M as of Mar 31, 2026, up from $145M at Dec 31, 2025; includes $164M net from Feb 2026 offering.
- Cash runway expected into late 2027 to support clinical milestones; lead program VMT-α-NET advancing to Cohort 4 and meningioma cohort.
- VMT01 (melanoma) dosing cohorts closed after 10 patients treated at 3.0 mCi; PSV359 (FAP) Cohort 3 open.
- Chicago manufacturing site on track to complete construction in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/0001193125-26-216777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/catx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer